drugset / Trial / NCT05602675
A Drug Interaction Study of LY3871801 in Healthy Participants
Non-randomizedSequentialOpen-labelBasic science
Summary
The main purpose of this study is to determine the effect of LY3871801 when administered orally on the levels of methotrexate (part 1), drug cocktail (warfarin, dextromethorphan, and midazolam) and repaglinide (part 2) in the blood stream when administered orally in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 25 days for each participant.
Timeline
- Start
- 2022-11-02
- Primary completion
- 2023-03-29
- Completion
- 2023-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dextromethorphan | Unknown | — | Oral |
| Subject | Methotrexate | Small molecule | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | OCADUSERTIB | Small molecule | — | Oral |
| Subject | Repaglinide | Small molecule | — | Oral |
| Subject | Warfarin | Small molecule | — | Oral |
Indications
No indication recorded.